Elena Prado-Mel

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Systematic Review

Community Dwelling

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Isabel María Carrión-Madroñal, Rocío Díaz Acedo, Santiago José Lora-Escobar, Eloisa Naranjo-Llamas, Didiana Jaramillo-Ruiz, Silvia Artacho-Criado, Elena Prado-Mel
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study. Future oncology (London, England) (2024)
Rocío Jiménez Galán, Elena Prado-Mel, María Alvarez de Sotomayor, Laila Abdel-Kader Martin
Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. Biology 12 (2) (2023)
Rocío Jiménez Galán, Elena Prado-Mel, María Alvarez de Sotomayor, Laila Abdel-Kader Martin
Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. Biology 12 (2) (2023)
Rocío Jiménez Galán, Elena Prado-Mel, María Alvarez de Sotomayor, Laila Abdel-Kader Martin
Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. Biology 12 (2) (2023)
Rocío Jiménez Galán, Elena Prado-Mel, Maria Antonia Pérez-Moreno, Estefanía Caballano-Infantes, Sandra Flores Moreno
Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population. Biology 10 (9) (2021)